All In Biotech

Drug Trial Radar · NCT02507167

Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

Impact of Two Genetic Variants of OATP 1B3 or MRP 2 or Rifampin Mediated Transporter Inhibition on Systemic Disposition and Biological Efficacy of CCK-8 in 36 Healthy Male Individuals

Last checked: Nov 19, 2026Latest source record: Jul 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Nov 2012

Primary completion

Jul 2013

Study completion Dec 2014

Sponsor

Lead sponsor
University Medicine GreifswaldAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2 on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a single-dose of the transporter inhibitor rifampin (600 mg) on the systemic disposition of endogenously formed CCK-8. Endogenous CCK-8 secretion will be induced by a single-dose standardized liquid mixed meal.

Conditions

  • Gastrointestinal Hormones

Interventions

  • mixed mealDietary supplement

    250 ml Fortimel compact (chocolate)

  • RifampinDrug

    oral rifampin administration (600 mg EREMFAT®)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CCK-8Time frame: 3 h 15 min up to 2 h 15 min before and 5, 10, 15, 20, 25, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4 h after mixed meal

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Clinical Pharmacology

    Greifswald, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.